Top Markets
Coin of the day
Abivax S.A. Abivax S.A.

Abivax S.A.

ABVX
Rang in aandelen #2071
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Aandeelprijs
$123.36
Marktkapitalisatie
$10.75B
Verandering (1 dag)
6.01%
Verandering (1 jaar)
62.32%
Land
FR
Handel Abivax S.A. (ABVX)

Categorie

Dividendgeschiedenis van Abivax S.A. (ABVX)
Abivax S.A. (aandelsymbool: ABVX) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor Abivax S.A. (ABVX) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
0.00%
US
0.00%
NL
0.00%
US
64.00%
AU
0.00%
CH